Thank you, Cystic Fibrosis Foundation, for your trust and support! We are honored to work together in advancing innovative treatments for cystic fibrosis patients.
We have invested an additional $5 million in BiomX to support a Phase 2b clinical trial to test the effectiveness of its bacteriophage (phage) therapy in treating chronic Pseudomonas aeruginosa infections — the second most common type of lung infection in people with cystic fibrosis. Phage therapy uses phages (bacteria-specific viruses) to kill specific bacterial strains that are causing an infection. “We continue to look for innovative ways to treat chronic and drug-resistant infections in people with CF,” said Tiffany Burnett, senior director of biopharma programs at the Cystic Fibrosis Foundation. “These types of trials are important as we seek to move past individual reports of success to determine whether phage therapy is a viable treatment option for the broader CF population.”